PEP005
Sponsors
Peplin
Conditions
Actinic KeratosesActinic KeratosisBasal Cell CarcinomaCarcinoma, Squamous CellKeratosisSuperficial Basal Cell CarcinomaWarts
Phase 1
Pharmacokinetic Study to Evaluate the Extent of Systemic Absorption of PEP005
CompletedNCT00544258
Start: 2007-10-31End: 2008-05-31Updated: 2015-02-12
The Purpose of This Study is to Determine Whether Topical Application of PEP005 is Safe for the Treatment of Common Wart(s)
WithdrawnNCT00546611
Start: 2007-10-31Updated: 2016-01-28
Phase 2
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Actinic Keratoses
CompletedNCT00107965
Start: 2005-03-31End: 2005-09-30Target: 60Updated: 2015-03-25
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Superficial Basal Cell Carcinoma
CompletedNCT00108134
Start: 2005-03-31End: 2006-03-31Target: 60Updated: 2008-12-24
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Nodular Basal Cell Carcinoma
CompletedNCT00108121
Start: 2005-03-31End: 2006-05-31Target: 60Updated: 2015-01-19
Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel
CompletedNCT00239135
Start: 2005-09-30End: 2005-12-31Target: 34Updated: 2015-03-25
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Cutaneous Squamous Cell Carcinoma In Situ
CompletedNCT00329121
Start: 2006-05-31End: 2006-12-31Target: 24Updated: 2015-01-19
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
CompletedNCT00375739
Start: 2006-09-30End: 2007-06-30Target: 200Updated: 2016-01-28
A Study to Determine the Optimal Tolerated Regime and Safety of PEP005 Topical Gel
CompletedNCT00427050
Start: 2007-01-31End: 2007-11-30Target: 50Updated: 2015-09-14
To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC
CompletedNCT00432185
Start: 2007-02-28End: 2010-03-31Updated: 2016-02-15